Amgen Inc. (NASDAQ:AMGN) and GSK plc (NYSE:GSK) are reportedly set to announce their partnership with TrumpRx.gov. This collaboration is set to offer substantial discounts on prescription drugs.

This move will augment the total number of discounted prescription medications available on the platform to 54, from five different pharmaceutical companies, according to a report by FOX Business on Friday.

Amgen will offer an 80% discount on Amjevita, a medication used for rheumatoid arthritis, psoriasis, and ulcerative colitis. The drug, originally priced at $1,484, will be available for $299 on TrumpRx.gov. Additionally, Amgen plans to list Aimovig and Repatha for discounts of 62%.

Meanwhile, GSK will offer a 55% discount on Incruse, a medication for COPD, pricing it at $159. The company also plans to list Arnuity, Relenza, and Anoro at discounts ranging from 10% to 51%.

Amgen and GSK did not immediately respond to Benzinga‘s request for comment.

TrumpRx Expands

President Donald Trump announced the new website, TrumpRx.gov, earlier this year, alongside Administrator of the Centers for Medicare & Medicaid Services, Mehmet Oz and Airbnb co-founder, Joe Gebbia, allowing consumers to search for discounted drug prices and print coupons, with 40 medicines from companies including AstraZeneca PLC (NYSE:AZN), Eli Lilly And Co.  (NYSE:LLY), EMD Serono, Novo Nordisk (NYSE:NVO), and Pfizer Inc. (NYSE:PFE) made available at launch.

Amid pressure from Trump and potential tariff threats, these companies have agreed to most-favoured-nation pricing (MFN).

Notably, the TrumpRx website does not sell medicines directly. Instead, it lets consumers search for medications, compare discounted prices, and print coupons to redeem those discounts at pharmacies or through manufacturers' websites.

Experts Divided On Trump Rx

Stephen Ubl, CEO of The Pharmaceutical Research and Manufacturers of America, told Fox Business that government-imposed MFN policies could hurt U.S. competitiveness, reduce funding for R&D, slow medical innovation, and increase reliance on China, without addressing insurance practices that raise patient costs.

However, earlier this month, Costplusdrugs.com CEO Mark Cuban defended TrumpRx, urging patience and supporting efforts to make medications more affordable, emphasizing the urgency of timely healthcare access.

"Give them a chance," Cuban said. "Anything that opens the door for lower price medications I’m a fan of."

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by a Benzinga editor.

Image via Shutterstock